10-Q: McKesson Q1 Profit Dips Amid Rite Aid Bankruptcy Charge

McKesson Corporation reported a 14% decline in net income for the first fiscal quarter of 2026, primarily due to a significant bad debt provision related to Rite Aid's second bankruptcy filing, despite robust revenue growth.

Summary

• Revenues increased by 23% to $97.83 billion for the three months ended June 30, 2025, compared to $79.28 billion in the prior year period, driven by market growth in the U.S. Pharmaceutical segment.
• Net income attributable to McKesson Corporation decreased by 14% to $784 million, down from $915 million in the prior year period.
• Diluted earnings per common share (EPS) attributable to McKesson Corporation decreased by 11% to $6.25, from $7.00 in the prior year period.
• Gross profit increased by 4% to $3.28 billion, up from $3.15 billion in the prior year period.
• Operating income slightly increased to $1.04 billion from $1.03 billion in the prior year period.
• A provision for bad debts of $189 million was recorded in the U.S. Pharmaceutical segment due to Rite Aid Corporation's second Chapter 11 bankruptcy filing.
• Completed the acquisition of an 80% controlling interest in PRISM Vision Holdings, LLC for $874 million in cash on April 1, 2025.
• Completed the acquisition of a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for $2.5 billion in cash on June 2, 2025.
• Announced the intention to separate the Medical-Surgical Solutions segment into an independent company.
• Returned $671 million to shareholders through $581 million in common stock repurchases and $90 million in dividend payments.
• The Board of Directors raised the quarterly dividend from $0.71 to $0.82 per common share on July 29, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While net income and EPS declined due to specific charges (Rite Aid, lower antitrust settlements, higher taxes), the company demonstrated strong revenue growth, strategic acquisitions for future expansion, and continued commitment to shareholder returns through dividends and share repurchases. The ongoing opioid litigation remains a significant financial overhang, but the company is actively managing its portfolio and pursuing efficiency initiatives.

Positives

• Total revenues increased by 23% to $97.83 billion, driven by strong market growth in the U.S. Pharmaceutical segment, including higher volumes from retail national account customers and growth in specialty pharmaceuticals.
• Gross profit increased by 4% to $3.28 billion, primarily from growth in specialty pharmaceuticals and retail national account customers in the U.S. Pharmaceutical segment, and higher volumes in the Prescription Technology Solutions segment.
• Operating income saw a slight increase to $1.04 billion.
• The Prescription Technology Solutions segment's operating profit increased by 25%, driven by increased volumes from technology services.
• The Medical-Surgical Solutions segment's operating profit increased by 18%, primarily due to lower expenses from business rationalization initiatives.
• Significant strategic acquisitions of PRISM Vision ($874 million) and Core Ventures ($2.5 billion) expand the company's presence in ophthalmology and community oncology.
• Demonstrated commitment to shareholder returns with $581 million in common stock repurchases and a dividend increase from $0.71 to $0.82 per share.
• Net cash used in operating activities decreased by $462 million compared to the prior year, indicating improved operational cash flow efficiency.

Negatives

• Net income attributable to McKesson Corporation decreased by 14% to $784 million.
• Diluted earnings per common share decreased by 11% to $6.25.
• A significant provision for bad debts of $189 million was recorded due to the second bankruptcy filing of Rite Aid Corporation.
• Other income, net, decreased by $66 million, primarily due to a prior year net gain of $110 million from equity investments not recurring in the current period.
• Income tax expense increased by 77% to $220 million, leading to a higher reported income tax rate of 20.9% compared to 11.4% in the prior year.
• Restructuring, impairment, and related charges, net, increased significantly to $47 million from $10 million in the prior year period, reflecting ongoing enterprise-wide initiatives.

Risks

• Ongoing opioid-related litigation matters pose a significant financial risk, with an estimated accrued liability of $6.377 billion as of June 30, 2025, and potential for material adverse impacts on financial position, cash flows, or results of operations.
• The second bankruptcy filing of Rite Aid Corporation resulted in a $189 million provision for bad debts, highlighting customer credit risk.
• The company is subject to various claims and legal proceedings, including governmental investigations, which could result in substantial payments, injunctions, or changes to business operations.
• Fluctuations in foreign currency exchange rates could have a material adverse impact on financial results reported in U.S. dollars.
• Changes in interest rates could impact the fair value of debt and financing costs.
• The company's ability to estimate projected cash flows for goodwill impairment testing could be adversely affected by government actions, increased regulatory uncertainty, and material changes in key market assumptions.

Future Outlook

The company anticipates total charges related to enterprise-wide restructuring initiatives of $650 million to $700 million, primarily consisting of employee severance and facility exit costs, expected to be substantially complete by fiscal 2028. The company expects to classify the assets and liabilities of its Norway retail and distribution businesses as held for sale in its next quarterly financial statements. The company does not expect the provisions of the recently enacted One Big Beautiful Bill Act (OBBBA) to have a material impact on its consolidated financial position, results of operations, or cash flows. The company anticipates continuing to pay quarterly cash dividends, with future payments dependent on earnings, financial condition, capital requirements, and other factors.

Management Comments

• We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere.
• Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.
• We believe the reserves maintained and expenses and credits recorded to date for Rite Aid trade accounts receivable are appropriate and consistent with our accounting policy and assessment of the information currently available.
• We believe we have valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and we intend to mount a vigorous defense in such matters.
• We expect our available cash generated from operations and our short-term investment portfolio, together with our existing sources of liquidity from our credit facilities, commercial paper program, and other borrowings will be sufficient to fund our short-term and long-term capital expenditures, working capital, and other cash requirements.
• We remain adequately capitalized, including access to liquidity from our $4.0 billion revolving credit facility and $1.0 billion 364-day credit facility.
• At June 30, 2025, we were in compliance with all debt covenants, and believe we have the ability to continue to meet our debt covenants in the future.

Industry Context

McKesson's strategic acquisitions in ophthalmology (PRISM Vision) and community oncology (Core Ventures) reflect a broader trend in the healthcare industry towards vertical integration and specialization, aiming to enhance service offerings and capture value across the patient care continuum. The planned separation of the Medical-Surgical Solutions segment indicates a focus on streamlining operations and potentially unlocking value by allowing each entity to pursue its distinct strategic priorities. The ongoing opioid litigation continues to be a significant industry-wide challenge for pharmaceutical distributors, impacting financial results and requiring substantial legal and settlement provisions.

Comparison to Industry Standards

• The company's revenue growth of 23% significantly outpaced general pharmaceutical distribution market growth, indicating strong performance in its core U.S. Pharmaceutical segment, particularly with retail national account customers and specialty pharmaceuticals.
• The acquisition of PRISM Vision and Core Ventures aligns with strategies seen in other large healthcare service providers like Optum (UnitedHealth Group) and CVS Health, which have expanded into provider services and specialty care to create integrated healthcare delivery models.
• The $189 million bad debt provision from Rite Aid's bankruptcy highlights the inherent credit risk in the pharmaceutical distribution sector, a risk managed by competitors like Cardinal Health and AmerisourceBergen through robust credit management and diversification.
• The ongoing opioid litigation and associated liabilities are a shared burden among the 'Big Three' pharmaceutical distributors (McKesson, Cardinal Health, AmerisourceBergen), with McKesson's $6.377 billion accrued liability reflecting its portion of the broader industry settlements and ongoing legal challenges.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in numerous opioid-related cases across the U.S., Puerto Rico, and Canada, with an estimated accrued liability of $6.377 billion as of June 30, 2025, for U.S. governmental entities and certain non-governmental plaintiffs.
• In the City of Baltimore opioid trial, a jury verdict of approximately $192 million in compensatory damages was returned on November 12, 2024, which was subsequently reduced to $37 million by the court on June 12, 2025. The company plans to appeal the verdict.
• The U.S. Supreme Court denied review of the relator's petition in the United States ex rel. Omni Healthcare, Inc. v. US Oncology, Inc. qui tam complaint, affirming the dismissal of the amended complaint.
• The company received $8 million from antitrust settlements related to lawsuits against a brand manufacturer for delaying generic drugs from entering the market.
• The State of New York agreed to pay the company $28 million to settle the Opioid Stewardship Act surcharge assessment, with payment appropriations included in the Fiscal Year 2026 budget.

Stakeholder Impact

• Shareholders: Impacted by decreased net income and EPS, but positively by increased dividends and ongoing share repurchase programs. The strategic acquisitions and divestitures aim to enhance long-term value.
• Customers (Rite Aid): The $189 million bad debt provision highlights the financial impact of customer bankruptcies on the company.
• Employees: Affected by enterprise-wide restructuring initiatives, which include cost reduction efforts and may involve severance and other employee-related costs, but aim to streamline the organization for long-term growth.
• Governmental Entities & Native American Tribes: Continue to receive payments under opioid settlement agreements, with $497 million paid in July 2025.
• Biopharma Companies & Care Providers: Benefit from McKesson's expanded services through acquisitions like PRISM Vision and Core Ventures, enhancing access to specialized care and technology solutions.

Next Steps

• Substantially complete enterprise-wide restructuring initiatives by fiscal 2028.
• Classify assets and liabilities of Norway retail and distribution businesses as held for sale in the next quarterly financial statements.
• Continue to pay quarterly cash dividends, subject to Board discretion and financial factors.
• Monitor the appeal process for the Baltimore opioid trial verdict and potential abatement relief.

Key Dates

Recommendation

While McKesson demonstrated strong top-line growth and made significant strategic acquisitions, the decline in net income and EPS due to the substantial Rite Aid bad debt provision and higher tax expense presents a mixed financial picture. The ongoing opioid litigation remains a material contingent liability. However, the company's commitment to shareholder returns (dividends, buybacks) and its proactive portfolio optimization (Medical-Surgical spin-off, Norway divestiture) suggest a resilient long-term strategy. Given the balance of growth drivers and financial headwinds, a 'hold' recommendation is appropriate for investors to observe the execution of strategic initiatives and the resolution of litigation.

Keywords

Healthcare services, Pharmaceutical distribution, Medical-surgical supplies, Prescription technology, Oncology, Acquisitions, Divestitures, Opioid litigation, Earnings, Revenue, Share repurchase, Dividend, Debt offering, SEC filing